Conference Coverage
Conference Coverage
Newly diagnosed mantle cell lymphoma is ‘one of the hardest consultations’
NEW YORK – Maintenance therapy puts off life-disrupting autologous stem cell transplantation, perhaps for what may be several years, but relapse...
Conference Coverage
Thousands expected to get CAR T-cells by 2018
Kite Pharma has a Los Angeles–area facility capable of processing T-cell specimens from 4,000 to 5,000 patients a year, according to Christine...
Conference Coverage
Obinutuzumab vs. rituximab weighed as follicular lymphoma therapy
A broader view indicates rituximab may be preferred depending on a patient’s status and priorities.
Conference Coverage
Inhibitor exhibits activity against hematologic malignancies
A dual kinase inhibitor is active against a range of hematologic malignancies, according to preclinical research. Investigators found that ASN002...
Conference Coverage
Reduced-intensity conditioning may not preserve fertility in young girls after bone marrow transplant
ORLANDO – Talking with a child who is about to undertake chemo about preserving her fertility may be the furthest thing from everyone’s mind, but...
Conference Coverage
Inhibitor produces durable responses in rel/ref iNHL
WASHINGTON, DC—An investigational drug can produce durable responses and has a manageable safety profile in patients with relapsed or refractory...
Conference Coverage
Half of patients retain response to CAR T-cell therapy
WASHINGTON, DC—Roughly half of patients who responded to chimeric antigen receptor (CAR) T-cell therapy in the ZUMA-1 trial have retained that...
Conference Coverage
Venetoclax produces durable effects in relapsed/refractory CLL
ORLANDO – Venetoclax may provide durable responses – even with treatment discontinuation – in patients with relapsed or refractory chronic...
Conference Coverage
Advanced CLL treatment approach depends on comorbidity burden
The choice of first-line therapy in symptomatic chronic lymphocytic leukemia patients depends largely on comorbidity burden.
Conference Coverage
Pathogenesis of breast-implant-associated ALCL
SAN FRANCISCO—A small study suggests an abnormal immune response characterized by the production of interleukin-13 (IL-13) underlies the...